Case Reports
No histologic evidence of foetal cardiotoxicity following exposure to maternal hydroxychloroquine
D. Friedman1, L. Lovig2, M. Halushka3, R.M. Clancy4, P.M. Izmirly5, J.P. Buyon6
- Paediatric Cardiology, New York Medical College, USA.
- Paediatric Cardiology, Children’s and Women’s Physicians of Westchester LLP, Norwalk, CT, USA.
- Pathology, Johns Hopkins Medicine, Baltimore, MD, USA.
- Medicine, Division of Rheumatology, New York University School of Medicine, New York, USA.
- Medicine, Division of Rheumatology, New York University School of Medicine, New York, USA.
- Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, USA. jill.buyon@nyumc.org
CER10192
2017 Vol.35, N°5
PI 0857, PF 0859
Case Reports
Free to view
(click on article PDF icon to read the article)
PMID: 28598777 [PubMed]
Received: 19/12/2016
Accepted : 28/03/2017
In Press: 06/06/2017
Published: 15/09/2017
Abstract
It is currently recommended that hydroxychloroquine (HCQ) be maintained during pregnancy in patients with systemic lupus erythematosus. Recent data suggest that this Toll-like receptor inhibitor may also reduce the recurrence rate of anti-SSA/Ro associated congenital heart block (CHB). This case report describes a unique situation in which a CHB-afflicted, HCQ-exposed pregnancy was electively terminated. The heart did not reveal any characteristic features of cardiotoxicity, providing further evidence supporting the safety of foetal exposure to HCQ.